A--Drug Manufacturing and Formulation Program (DMFP)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) NIDA, under the Department of Health and Human Services, has awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP). These awards, totaling a maximum ordering value of $49,999,999.00, establish a framework for health R&D services, specifically basic research related to drug manufacturing and formulation. The initial task orders were issued concurrently with the awards.
Contract Details
- Type: Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) contracts
- Maximum Ordering Value: $49,999,999.00
- Ordering Period: May 4, 2026, through May 3, 2036 (10 years)
- Award Date: May 4, 2026
- Initial Task Orders: Issued May 4, 2026, through July 3, 2026, for $5,000.00 each (Firm-Fixed Price).
- Place of Performance: Alachua, FL, United States
- Product/Service Code: AN11 (Health R&D Services; Health Care Services; Basic Research)
- Set-Aside: None specified
Purpose
These awards support the Drug Manufacturing and Formulation Program (DMFP), focusing on health R&D services and basic research. The IDIQ structure provides a flexible mechanism for the National Institutes of Health NIDA to procure necessary services over the next decade.
Additional Information
For further details, contact Rieka N. Plugge at rieka.plugge@nih.gov or Kelly Dempsey at kelly.dempsey@nih.gov.